Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae

• Váldodahkkit: Nader S. Abutaleb (Dahkki), Ahmed E. M. Elhassanny (Dahkki), Alessio Nocentini (Dahkki), Chad S. Hewitt (Dahkki), Ahmed Elkashif (Dahkki), Bruce R. Cooper (Dahkki), Claudiu T. Supuran (Dahkki), Mohamed N. Seleem (Dahkki), Daniel P. Flaherty (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2022-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Neisseria gonorrhoeae is a high-priority pathogen of concern due to the growing prevalence of resistance development against approved antibiotics. Herein, we report the anti-gonococcal activity of ethoxzolamide, the FDA-approved human carbonic anhydrase inhibitor. Ethoxzolamide displayed an MIC50, a...